Mammalian Cell Fermentation Technology Global Market Report 2024

Mammalian cell fermentation technology refers to the process of cultivating mammalian cells under controlled conditions to produce biopharmaceuticals, vaccines, or other biological products. This technology involves optimizing cell growth and protein expression in bioreactors or fermenters, ensuring the production of high-quality and consistent yields of desired therapeutic proteins or substances.

The main types of mammalian cell fermentation technology include Chinese hamster ovary (CHO) cell fermentation, human embryonic kidney (HEK) cell fermentation, baby hamster kidney (BHK) cell fermentation, murine myeloma cell fermentation, and other types. Chinese hamster ovary (CHO) cell fermentation is a biotechnological process used in the production of therapeutic proteins, such as monoclonal antibodies and recombinant proteins. The various applications of mammalian cell fermentation technology include monoclonal antibodies, recombinant proteins, vaccines, hormones, enzymes, and other products. The end-users of this technology include biopharmaceutical companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and academic and research institutes.

The mammalian cell fermentation technology market research report is one of a series of new reports that provides mammalian cell fermentation technology market statistics, including mammalian cell fermentation technology industry global market size, regional shares, competitors with a mammalian cell fermentation technology market share, detailed mammalian cell fermentation technology market segments, market trends, and opportunities, and any further data you may need to thrive in the mammalian cell fermentation technology industry. This mammalian cell fermentation technology research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mammalian cell fermentation technology market size has grown rapidly in recent years. It will grow from $46.05 billion in 2023 to $51.29 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historic period can be attributed to several factors, including increased demand for biologics and biosimilars, a heightened focus on personalized medicine, an increased output of biopharmaceuticals, and a rising demand for scalable and effective cell culture methods.

The mammalian cell fermentation technology market size is expected to see rapid growth in the next few years. It will grow to $80.16 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The expected growth in the forecast period can be attributed to several factors, including the increasing prevalence of chronic diseases, rising investments by multinational corporations, the growing frequency of chronic diseases, the increasing adoption of advanced bioprocessing techniques, rising investment in research and development of novel recombinant proteins, and the growing demand for cancer therapies. Major trends anticipated during this period include technological advancements in cell culture and bioreactor design, the development of next-generation bioprocessing technologies, the integration of multi-omics approaches, and technology-driven automation.

The increasing demand for biologics is anticipated to drive the growth of the mammalian cell fermentation technology market in the future. Biologics, which are medical products derived from living organisms or their components, are often used to treat diseases such as cancer, autoimmune disorders, and infectious diseases. The growing demand for biologics is driven by advancements in biotechnology, their effectiveness in treating prevalent chronic diseases, regulatory approvals, and increased investment in research and development. Mammalian cell fermentation technology is crucial for producing complex biologics, meeting the rising demand for personalized and targeted therapeutics. Its scalability, versatility, and ability to produce high-quality proteins foster innovation in the biopharmaceutical industry. For example, the National Library of Medicine reported in February 2024 that the Food and Drug Administration (FDA) approved 55 new drugs in 2023, including 29 new chemical entities (NCEs) and 25 new biological entities (NBEs), marking a 50% increase compared to the 37 approvals in 2022. Therefore, the growing demand for biologics is driving the expansion of the mammalian cell fermentation technology market.

Leading companies in the mammalian cell fermentation technology market are developing innovative technologies, such as mammalian cell culture, to bolster their market position. Mammalian cell culture is a vital tool in biomanufacturing, research, and regenerative medicine, enabling the production of therapeutic proteins, vaccines, and functional cells or tissue analogs. For instance, in February 2021, Culture Bioscience, a US-based biotechnology company, introduced cloud bioreactors for mammalian cell culture. This groundbreaking technology provides a fully cloud-based platform for scalable cell culture research, representing a significant advancement in bioprocessing. These cloud bioreactors utilize remote monitoring and control technologies to offer real-time data analysis and decision-making from any location with internet access, enhancing scalability, flexibility, and collaboration in bioprocess and biomanufacturing development.

In February 2024, Chrysea Limited, an Ireland-based biotechnology company, acquired Rodon Biologics from the Iberfar Group for an undisclosed amount. With this acquisition, Chrysea aims to strengthen its synthetic biology and biopharmaceutical development capabilities by integrating Rodon Biologics' expertise in protein engineering, cell-line development, precision fermentation, downstream processing, formulation, analytics, and production. Rodon Biologics, a Portugal-based manufacturer of biological products, operates in mammalian cell fermentation technology.

Major companies operating in the mammalian cell fermentation technology market are AbbVie Inc., Thermo Fisher Scientific Inc, AstraZeneca PLC, Roche Holdings Inc., Merck KGaA, AGC Group, Lonza Group Ltd., Boehringer Ingelheim GmbH, Catalent Inc., Sartorius AG, Samsung Biologics Co. Ltd., WuXi Biologics, Biocon Limited, Eppendorf AG, KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies, Avid Bioservices Inc., BiOZEEN, Nordmark Pharma GmbH, Scorpius BioManufacturing Inc.

North America was the largest region in the mammalian cell fermentation technology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mammalian cell fermentation technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mammalian cell fermentation technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mammalian cell fermentation technology market consists revenues earned by entities by providing services such as cell line development, process development, cell culture and fermentation, analytical and quality control services, and formulation and fill-finish services. The market value includes the value of related goods sold by the service provider or included within the service offering. The mammalian cell fermentation technology market also includes of sales of biosimilars, cell and gene therapy products, diagnostic enzymes and proteins, and therapeutic proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.